Medical Economics March 27, 2025
Key Takeaways
- Proposed tariffs threaten the U.S. biotech industry’s reliance on imported components, risking increased costs and delayed treatments.
- Nearly 90% of U.S. biotech companies depend on imports for at least half of their FDA-approved products, highlighting vulnerability to trade shifts.
- Tariffs could slow medical innovation, with firms needing new partners and facing potential delays in regulatory filings.
- Logistical challenges include lengthy timelines for finding alternative suppliers, potentially stalling treatment development and production.
- Industry leaders advocate for policies supporting domestic manufacturing while warning of tariffs’ negative impacts on the biotech sector.
Imported components account for almost half of US companies’ FDA-approved products
A survey from the Biotechnology Innovation Organization (BIO) highlights the deep global integration of the biomedical...
Today's Sponsors
Today's Sponsor